SG11201501039WA - Hyaluronic acid-based drug delivery systems - Google Patents

Hyaluronic acid-based drug delivery systems

Info

Publication number
SG11201501039WA
SG11201501039WA SG11201501039WA SG11201501039WA SG11201501039WA SG 11201501039W A SG11201501039W A SG 11201501039WA SG 11201501039W A SG11201501039W A SG 11201501039WA SG 11201501039W A SG11201501039W A SG 11201501039WA SG 11201501039W A SG11201501039W A SG 11201501039WA
Authority
SG
Singapore
Prior art keywords
drug delivery
hyaluronic acid
delivery systems
based drug
systems
Prior art date
Application number
SG11201501039WA
Inventor
Subramanian Venkatraman
Leonardus Kresna Widjaja
Tina Tzee Ling Howden
Original Assignee
Univ Nanyang Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nanyang Tech filed Critical Univ Nanyang Tech
Publication of SG11201501039WA publication Critical patent/SG11201501039WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201501039WA 2012-09-06 2013-09-06 Hyaluronic acid-based drug delivery systems SG11201501039WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261697296P 2012-09-06 2012-09-06
PCT/SG2013/000389 WO2014039012A1 (en) 2012-09-06 2013-09-06 Hyaluronic acid-based drug delivery systems

Publications (1)

Publication Number Publication Date
SG11201501039WA true SG11201501039WA (en) 2015-03-30

Family

ID=50237478

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201501039WA SG11201501039WA (en) 2012-09-06 2013-09-06 Hyaluronic acid-based drug delivery systems
SG10201701773UA SG10201701773UA (en) 2012-09-06 2013-09-06 Hyaluronic Acid-Based Drug Delivery Systems

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201701773UA SG10201701773UA (en) 2012-09-06 2013-09-06 Hyaluronic Acid-Based Drug Delivery Systems

Country Status (6)

Country Link
US (1) US9987367B2 (en)
EP (1) EP2892564A4 (en)
JP (1) JP6408469B2 (en)
CN (1) CN104602712A (en)
SG (2) SG11201501039WA (en)
WO (1) WO2014039012A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
US10335515B2 (en) 2013-09-25 2019-07-02 The University Of Kansas Hydrogel precursors having nanoparticles
US9782345B2 (en) 2013-10-17 2017-10-10 Jade Therapeutics, Inc. Ocular composition and method
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
CN104511022A (en) * 2014-05-10 2015-04-15 上海珀理玫化学科技有限公司 Medicinal composition of paclitaxel
CN104511020A (en) * 2014-05-10 2015-04-15 上海珀理玫化学科技有限公司 Medicinal composition of paclitaxel
JP6506311B2 (en) * 2014-06-05 2019-04-24 ユニバーシティ・オブ・ジ・ウィトウォーターズランド・ヨハネスブルクＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｈｅ Ｗｉｔｗａｔｅｒｓｒａｎｄ， Ｊｏｈａｎｎｅｓｂｕｒｇ Wound dressing
WO2016049360A1 (en) 2014-09-24 2016-03-31 Massachusetts Institute Of Technology Shear-thinning self-healing networks
AU2015360469B2 (en) * 2014-12-10 2021-03-25 Incept, Llc Hydrogel drug delivery implants
US11452759B2 (en) * 2015-01-19 2022-09-27 Technion Research & Development Foundation Limited Ubiquitin ligase KPC1 promotes processing of P105 NF-κB1 to p50, eliciting strong tumor suppression
US20180117058A1 (en) * 2015-10-07 2018-05-03 Cormedix Inc. Skin-penetrating formulation of taurolidine
CN105288594A (en) * 2015-11-30 2016-02-03 武汉理工大学 Growth factor porous micro-sphere compound system coated by injectable hydrogel
TWI609701B (en) 2016-01-05 2018-01-01 國立交通大學 Compound prescription colloidal eyedrop gel and methods of making the same
CN106397795B (en) * 2016-08-31 2018-12-21 陕西佰傲再生医学有限公司 A kind of mixed transparent matter acid gel and preparation method thereof
US9763047B1 (en) 2016-09-28 2017-09-12 International Business Machines Corporation Anonymizing location data
WO2018213795A1 (en) * 2017-05-18 2018-11-22 The Board Of Trustees Of The Leland Stanford Junior University Targeted in situ therapeutic delivery of secreted factors from stem cells for treatment of damaged tissue
WO2019055594A1 (en) * 2017-09-13 2019-03-21 North Carolina State University Locally-induced adipose tissue browning by microneedle patch for obesity treatment
EP3840727A1 (en) * 2018-08-23 2021-06-30 Eric F. Bernstein Systems, devices and methods for applying anti-vegf compounds and using such compounds to treat skin conditions
CN109091468B (en) * 2018-09-29 2021-07-02 上海交通大学 Antibody, polypeptide and nucleic acid combined therapy targeting vector and preparation method and application thereof
EP3860613A4 (en) * 2018-10-01 2022-07-06 The Board of Trustees of the Leland Stanford Junior University Injectable hydrogels for controlled release of immunomodulatory compounds
US20220265695A1 (en) 2019-07-26 2022-08-25 Proqr Therapeutics Ii B.V. Opthalmic compositions comprising viscosifying polymers and nucleic acids
TWI712403B (en) * 2019-08-26 2020-12-11 長庚大學 Water glue dressing
CN112457481B (en) * 2019-09-06 2021-10-08 天津大学 Polyether macromolecule with conductive activity and end-epoxy-group hyperbranched structure and preparation method thereof
CN111467349B (en) * 2020-05-14 2021-06-01 华熙生物科技股份有限公司 Artificial tear and preparation method thereof
US11452703B2 (en) 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers
US20230149288A1 (en) * 2020-08-31 2023-05-18 VAIM Co.,Ltd. Biodegradable polymer dispersion, composition comprising same, and skin improvement system
CN112980925A (en) * 2021-04-06 2021-06-18 厦门大学附属厦门眼科中心有限公司 MicroRNA detection method based on DNA hydrogel electrochemiluminescence system
CN113398283B (en) * 2021-06-18 2022-12-27 上海市伤骨科研究所 Inhalable atomization microsphere based on biomembrane coupling, preparation method and application
CN113368034B (en) * 2021-06-23 2022-08-16 武汉天时维璟微生物科技有限公司 Soluble microneedle patch for treating septicemia and manufacturing method thereof
CN113736043B (en) * 2021-11-03 2022-05-20 北京华芢生物技术有限公司 pH response type hydrogel biological carrier and application
CN114767922B (en) * 2022-03-15 2023-09-12 青岛大学 Hyaluronic acid hydrogel carrying probiotics and preparation method and application thereof
CN114869862A (en) * 2022-04-24 2022-08-09 温州医科大学附属眼视光医院 Glaucoma surgery slow-release anti-scar membrane with drainage function and preparation method thereof
KR20240076105A (en) * 2022-11-23 2024-05-30 주식회사 바임 Biodegradable polymer dispersion, AND method for preparing thereof
US12005077B1 (en) * 2023-09-28 2024-06-11 Terry Earl Brady Broad-spectrum antimicrobial, biocompatible and preservative-free functionalized fullerenes ophthalmic solution with reactive oxygen species scavenging and advanced targeting, penetration, and hydration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3898783B2 (en) 1996-08-26 2007-03-28 久光製薬株式会社 Biodegradable hyaluronic acid crosslinked gel composition and biodegradable hyaluronic acid crosslinked gel preparation
DE69732308T2 (en) * 1996-09-27 2005-06-02 Jagotec Ag DRUG DISPOSAL SYSTEM WITH HYALURONIC ACID
WO2002055742A2 (en) * 2001-01-09 2002-07-18 Novartis Ag Rapid method for screening compounds for in vivo activity
EP1387676A2 (en) * 2001-05-01 2004-02-11 Angiotech Pharmaceuticals, Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
US20030157161A1 (en) * 2001-05-01 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
WO2004046200A1 (en) 2002-11-21 2004-06-03 Chugai Seiyaku Kabushiki Kaisha Sustained release drug carrier
AU2003901834A0 (en) 2003-04-17 2003-05-01 Clearcoll Pty Ltd Cross-linked polysaccharide compositions
JP2004323454A (en) 2003-04-25 2004-11-18 Chisso Corp Medicinal agent
WO2005054302A1 (en) 2003-12-05 2005-06-16 Chugai Seiyaku Kabushiki Kaisha Drug carrier and process for producing the same
ES2314354T3 (en) * 2004-11-09 2009-03-16 Novagali Pharma S.A. EMULSION OF WATER OIL TYPE WITH LOW CONCENTRATION OF CATIONIC AGENT AND POTENTIAL POSITIVE ZETA.
US9205046B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Enhanced stability of inverse thermal gelling composite hydrogels
US20070141134A1 (en) * 2005-12-16 2007-06-21 Kosak Matthew K Shielded micelles for polynucleotide delivery
KR100852944B1 (en) * 2007-02-15 2008-08-19 (주)아모레퍼시픽 Preparation method of chemically cross-linked hyaluronic acid hydrogel nanoparticles
US20090226531A1 (en) * 2008-03-07 2009-09-10 Allergan, Inc. Methods and composition for intraocular delivery of therapeutic sirna
US20120093914A1 (en) * 2008-11-24 2012-04-19 Moma Therapeutics Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration
US20120082717A1 (en) * 2009-06-05 2012-04-05 Snu R&Db Foundation Complex, multilayer using the same, and device coated with the multilayer
WO2013021249A1 (en) * 2011-08-10 2013-02-14 Glycores 2000 S.R.L. Degradation-resistant cross-linked, low-molecular-weight hyaluronate
US9901660B2 (en) * 2013-07-04 2018-02-27 Yeda Research And Development Co. Ltd. Low friction hydrogels and hydrogel-containing composite materials
US9956195B2 (en) * 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery

Also Published As

Publication number Publication date
SG10201701773UA (en) 2017-04-27
US20150250891A1 (en) 2015-09-10
WO2014039012A1 (en) 2014-03-13
US9987367B2 (en) 2018-06-05
EP2892564A1 (en) 2015-07-15
JP2015527391A (en) 2015-09-17
CN104602712A (en) 2015-05-06
EP2892564A4 (en) 2016-04-27
JP6408469B2 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
SG10201701773UA (en) Hyaluronic Acid-Based Drug Delivery Systems
HK1208387A1 (en) Drug delivery device
HK1208388A1 (en) Drug delivery device
HK1205928A1 (en) Ocular drug delivery system
IL245544A0 (en) Drug delivery system
HK1206655A1 (en) Drug delivery device
HK1206654A1 (en) Drug delivery device
GB201215193D0 (en) Order delivery system
HK1202826A1 (en) Medicament delivery devices
HRP20181707T1 (en) A drug delivery system
HK1205702A1 (en) Drug delivery device
EP2921152A4 (en) Drug dispensing system
HK1204258A1 (en) Drug dispensing system
ZA201309156B (en) Drug delivery system
SG10201609440WA (en) Multi-additive delivery system
HK1202465A1 (en) Drug delivery device
HK1211246A1 (en) Drug delivery device
HK1205704A1 (en) Drug delivery device
EP2917860A4 (en) Drug dispensing system
HUE049546T2 (en) Drug delivery device
HUE049542T2 (en) Drug delivery device
GB201218668D0 (en) Drug delivery device